Loading clinical trials...
Loading clinical trials...
This trial is conducted in Asia. The aim of this trial is to evaluate the efficacy and safety of recombinant human growth hormone (hGH) in subjects with idiopathic short stature in Korea.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novo Nordisk A/S
NCT02769975 · Adrenal Insufficiency, Growth Disorder, and more
NCT06382155 · Idiopathic Short Stature
NCT06309979 · Idiopathic Short Stature
NCT06662045 · Iron-Deficiency Anemia, Neurobehavioral Manifestations, and more
NCT03283852 · Disorders of Sex Development, Growth Disorders, and more
Novo Nordisk Investigational Site
Busan
Novo Nordisk Investigational Site
Daegu
Novo Nordisk Investigational Site
Seoul
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions